Home / Health / Lyme Vaccine Nears Approval After Trial Success
Lyme Vaccine Nears Approval After Trial Success
23 Mar
Summary
- Lyme disease vaccine candidate showed over 70% efficacy.
- It demonstrated 74.8% efficacy in a second planned analysis.
- An estimated 476,000 Lyme cases are diagnosed annually in the U.S.
An experimental Lyme disease vaccine developed by Pfizer and Valneva has shown promising results in a late-stage clinical trial, with reported efficacy rates exceeding 70%.
The vaccine, known as PF-07307405, achieved 73.2% efficacy after its fourth dose in an initial analysis, though it narrowly missed its primary goal due to fewer Lyme cases than anticipated in the trial.
However, a subsequent analysis met the efficacy target with a 74.8% success rate. This improved outcome has bolstered the companies' confidence and paved the way for submissions to regulatory authorities.
Lyme disease, transmitted by infected ticks, can cause symptoms including fever, headache, fatigue, and a characteristic rash. If untreated, it can progress to affect joints, the heart, and the nervous system.
The U.S. Centers for Disease Control and Prevention estimates approximately 476,000 people are diagnosed and treated for Lyme disease annually in the United States. Europe reports around 132,000 cases each year.
With no current vaccine available for Lyme disease following the discontinuation of GSK's Lymerix in 2002, this development offers significant hope for prevention.
Valneva previously indicated expectations for a potential launch of the vaccine in the second half of 2027, pending regulatory approvals.
